Filing identity and reporting period
Important identity mismatch: The request identifies PDS Biotechnology Corp., but the supplied Form 10-Q is for Edge Therapeutics, Inc. It covers the quarter ended September 30, 2016, and was signed November 1, 2016. The summary below reflects the supplied filing, not a PDS Biotechnology filing.
Business context
Edge was a clinical-stage biotechnology company with no approved products or commercial revenue. Its lead candidate, EG-1962, was in a Phase 3 trial for aneurysmal subarachnoid hemorrhage (aSAH); its second candidate, EG-1964, was in development for chronic subdural hematoma. The company said it expected to continue incurring significant research, development, and operating expenses.
Financial results and liquidity
| Metric | Three months ended September 30, 2016 | Nine months ended September 30, 2016 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $6.7 million | $18.0 million |
| General and administrative expense | $3.6 million | $10.5 million |
| Total operating expenses | $10.3 million | $28.6 million |
| Net loss | $10.8 million | $29.3 million |
| Loss per share, basic and diluted | $0.37 | $1.02 |
| Cash used in operating activities | Not provided for the quarter | $26.1 million |
At September 30, 2016, cash and cash equivalents were $112.8 million, down from $130.2 million at December 31, 2015. Total assets were $116.6 million and stockholders’ equity was $97.5 million. Debt was reported as $14.8 million long-term, with no short-term debt; the amended Hercules facility had $15.0 million drawn and allowed an additional $5.0 million draw subject to its terms. No profit margin is meaningful because the company had no revenue and reported operating losses.
Changes versus the comparable periods
- Third-quarter operating expenses increased 21% year over year; net loss increased 6% to $10.8 million. R&D expense rose 3%, while G&A rose 80%, including higher personnel, stock compensation, facilities, professional fees, and public-company costs.
- For the first nine months, operating expenses increased 62% and net loss increased 46% year over year. R&D growth primarily reflected higher clinical-trial costs and internal staffing; G&A growth reflected personnel, stock compensation, facilities, professional fees, and public-company expenses.
- Operating cash use increased from $15.0 million to $26.1 million for the nine-month period. Financing cash inflow fell to $9.1 million from $54.9 million in 2015, when preferred-stock proceeds were substantial.
Outlook, risks, and notable items
- Management said existing cash was expected to fund anticipated needs through the full readout of the planned EG-1962 Phase 3 trial, anticipated in 2018. This estimate is forward-looking and depends on trial design, progress, costs, and other assumptions; management cautioned that actual cash needs could be higher.
- Management expected an interim NEWTON 2 analysis in early 2018 and full-study results in late 2018. It expected data from a separate small EG-1962 study during 2017. For EG-1964, it planned formulation and nonclinical work in 2017 and said an IND filing in 2018 might follow, depending on results.
- Key risks include clinical-trial outcomes and timing, FDA requirements, regulatory approval, competition, manufacturing and vendor performance, intellectual-property protection, and the ability to obtain additional financing. The filing said there were no material changes to previously disclosed risk factors.
- In August 2016, the company paid Evonik a $1.0 million milestone after the first patient entered the EG-1962 Phase 3 trial. The license provides for up to $14.75 million in milestone payments in total, including amounts already paid, and mid-single-digit royalties on certain net sales.
- The company amended its Hercules loan in August 2016: $15.0 million was drawn, at a stated effective rate of 9.15% at quarter-end, with 18 months of interest-only payments followed by scheduled amortization. The debt is secured by substantially all assets other than intellectual property, and includes covenants, default remedies, and possible additional interest and prepayment charges.
- Other notable items included a $163,000 expense related to disposal of leasehold improvements and debt issuance costs, and a new office lease with approximately $3.1 million of future minimum payments. The company reported no material litigation and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is for Edge Therapeutics, Inc., not PDS Biotechnology Corp.
- Review EG-1962 Phase 3 enrollment, trial design, regulatory interactions, and the timing and outcome of planned analyses.
- Assess cash burn and whether the reported cash balance and management’s runway estimate remain adequate under changing trial costs or timelines.
- Review Hercules loan covenants, repayment schedule, security interest, and conditions for drawing the additional tranche.
- Check remaining Evonik milestone obligations, royalty terms, and any subsequent material clinical, financing, or regulatory developments.